TY - JOUR
T1 - Non-Hodgkin Lymphoma
T2 - Diagnosis and Treatment
AU - Ansell, Stephen M.
N1 - Publisher Copyright:
© 2015 Mayo Foundation for Medical Education and Research.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - Non-Hodgkin lymphomas are lymphoid malignant neoplasms with diverse biological and clinical behavior. Patients typically present with persistent painless lymphadenopathy, but some patients may present with constitutional symptoms or with involvement of organs other than the lymphoid and hematopoietic system. An accurate diagnosis, careful staging of the disease, and identification of adverse prognostic factors form the basis of treatment selection. Patients commonly receive chemoimmunotherapy as initial treatment, and radiation therapy may be added if patients have early-stage disease. Most patients respond well to treatment, but relapses are frequent and additional therapies including stem cell transplant are often needed. Because many subtypes of lymphoma remain incurable with current management strategies, clinical trials are in progress to identify novel therapies with promising activity in this disease.
AB - Non-Hodgkin lymphomas are lymphoid malignant neoplasms with diverse biological and clinical behavior. Patients typically present with persistent painless lymphadenopathy, but some patients may present with constitutional symptoms or with involvement of organs other than the lymphoid and hematopoietic system. An accurate diagnosis, careful staging of the disease, and identification of adverse prognostic factors form the basis of treatment selection. Patients commonly receive chemoimmunotherapy as initial treatment, and radiation therapy may be added if patients have early-stage disease. Most patients respond well to treatment, but relapses are frequent and additional therapies including stem cell transplant are often needed. Because many subtypes of lymphoma remain incurable with current management strategies, clinical trials are in progress to identify novel therapies with promising activity in this disease.
UR - http://www.scopus.com/inward/record.url?scp=84938598515&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938598515&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2015.04.025
DO - 10.1016/j.mayocp.2015.04.025
M3 - Article
C2 - 26250731
AN - SCOPUS:84938598515
SN - 0025-6196
VL - 90
SP - 1152
EP - 1163
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 8
ER -